ReviewCurrent issues in molecular biology2025
Revolution of Circulating Tumor DNA: From Bench Innovations to Bedside Implementations.
Review in Current issues in molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Non-Invasive Diagnosis of Early Breast Cancer: Current and Emerging Liquid Biopsy Biomarkers.Cancers · 2026Review
- Circulating Tumor DNA as a Biomarker of Treatment Response and Minimal Residual Disease in Diffuse Large B-Cell Lymphoma: A Literature Review.Journal of clinical medicine · 2026Review
- Integrating multi-omics data for next-generation cancer research and precision medicine.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Artificial intelligence-powered liquid biopsy in cancer: a paradigm shift in cancer detection and personalized care.Cancer cell international · 2026Review
- Circulating Tumor DNA in Breast Cancer: A Liquid Biopsy Revolution for Non-Invasive Genomic Profiling and Clinical Decision-Making.Breast cancer : basic and clinical research · 2026Review
- Peripheral blood biomarkers in PD-1/PD-L1 immunotherapy: distinguishing predictive from prognostic biomarkers.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Circulating tumor DNA (ctDNA), a newly developed cancer biomarker, consists of single- or double-stranded DNA fragments that are shed from tumor cells in primary or metastatic sites. They are released into peripheral blood and exhibit distinct characteristics associated with cancer, even in the early stages. With advancements in technology, ctDNA detection has become more diverse and precise, including digital Polymerase Chain Reaction (dPCR) and next-generation sequencing (NGS), among others. As a chronic disease that develops over an extended period, early detection is crucial for the accurate diagnosis and treatment of cancer and can significantly improve patient prognosis. Therefore, analyzing ctDNA features is important. Additionally, ctDNA can be used to assess post-surgical minimal residual disease (MRD), aiding in treatment decisions. Overall, ctDNA plays a crucial role in the progression of cancer and its treatment. This review summarizes the sources and features of ctDNA, the analytical techniques used, and its application in both solid and non-solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.